European Journal of Cancer
Volume 41, Issue 13 , Pages 1889-1910, September 2005

The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: An overview

Division of Cancer Prevention, National Cancer Institute, DHHS, Bethesda, MD 20892, USA

Received 25 April 2005; accepted 25 April 2005.

Abstract 

Chemoprevention is an innovative area of cancer research that focuses on the development of pharmacological, biological, and nutritional interventions to prevent, reverse, or delay carcinogenesis. Over the past two decades the Division of Cancer Prevention of the US National Cancer Institute has organized a research and development program to provide resources and infrastructure to the research community for the clinical evaluation of potential cancer preventive agents. This program now encompasses preclinical agent and molecular target identification, in vitro and in vivo screening, efficacy and intermediate endpoint testing, pharmacology and toxicology assessments, and finally chemical synthesis and manufacturing leading to Investigational New Drug applications and clinical studies. In this review, examples of agents currently in development, preclinical testing models, and phase 1 and 2 clinical studies are described. Continued commitment to cancer prevention will significantly reduce the economic and medical burden of cancer.

Keywords: Cancer prevention, Chemoprevention, Carcinogenesis, Drug development

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(05)00339-4

doi:10.1016/j.ejca.2005.04.016

European Journal of Cancer
Volume 41, Issue 13 , Pages 1889-1910, September 2005